GSKGlaxoSmithKlineRunning, no new patients
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 41 (final count)
- Started
- May 7, 2024
- Main results expected
- Dec 14, 2026
- Fully finished
- Sep 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Durable response rate for 12 months (DRR12) assessed by Blinded independent central review (BICR)
Measured over: Approximately 18 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06317311 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC